Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults.

Teng, Lida; Mizukami, Akiko; Ng, Cheryl; Giannelos, Nikolaos; Curran, Desmond; Sato, Tomohide; Lee, Christa; Matsuki, Taizo

Teng, Lida; Mizukami, Akiko; Ng, Cheryl; Giannelos, Nikolaos; Curran, Desmond; Sato, Tomohide; Lee, Christa; Matsuki, Taizo.

Afiliação

Teng L; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Mizukami A; GSK, 1-8-1 Akasaka, Minato-ku, Tokyo, 107-0052, Japan.
Ng C; GSK, Singapore, Singapore.
Giannelos N; GSK, Wavre, Belgium.
Curran D; GSK, Wavre, Belgium.
Sato T; GSK, 1-8-1 Akasaka, Minato-ku, Tokyo, 107-0052, Japan.
Lee C; GSK, Singapore, Singapore.
Matsuki T; GSK, 1-8-1 Akasaka, Minato-ku, Tokyo, 107-0052, Japan. taizo.2.matsuki@gsk.com.

Dermatol Ther (Heidelb) ; 12(6): 1447-1467, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35668295

Palavras-chave

Cost-effectiveness; Herpes zoster; Incremental cost-effectiveness ratio; Markov model; Older adults; Postherpetic neuralgia; Quality-adjusted life-years; Recombinant zoster vaccine; Shingles; Vaccination

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Dermatol Ther (Heidelb) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google